Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons
- PMID: 23140823
- DOI: 10.1016/j.ejca.2012.10.011
Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons
Comment in
-
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.Eur J Cancer. 2013 Mar;49(4):986-7. doi: 10.1016/j.ejca.2012.10.010. Epub 2012 Nov 5. Eur J Cancer. 2013. PMID: 23138000 No abstract available.
Comment on
-
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.Eur J Cancer. 2012 Nov;48(17):3171-6. doi: 10.1016/j.ejca.2012.05.022. Epub 2012 Jul 4. Eur J Cancer. 2012. PMID: 22766517 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
